These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26194080)

  • 1. Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes.
    Lim Y; Yoo S; Lee SA; Chin SO; Heo D; Moon JC; Moon S; Boo K; Kim ST; Seo HM; Jwa H; Koh G
    Endocrinol Metab (Seoul); 2015 Jun; 30(2):208-15. PubMed ID: 26194080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome.
    Barkas F; Elisaf M; Liberopoulos E; Liontos A; Rizos EC
    Atherosclerosis; 2016 Apr; 247():58-63. PubMed ID: 26868509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
    Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
    Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Among young Sri Lankan patients with diabetes, how do lipid profiles differ between those with and without metabolic syndrome?
    Katulanda GW; Dissanayake HA; Katulanda P; Matthews DR; Shine B
    Diabetes Metab Syndr; 2019; 13(5):3057-3063. PubMed ID: 30037759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study.
    Sattar N; Williams K; Sniderman AD; D'Agostino R; Haffner SM
    Circulation; 2004 Oct; 110(17):2687-93. PubMed ID: 15492304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of metabolic syndrome severity with cardiovascular health markers in adolescents.
    Lee AM; Gurka MJ; DeBoer MD
    Metabolism; 2017 Apr; 69():87-95. PubMed ID: 28285655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.
    Weinstock RS; Goldberg RB; Guyton JR; Mazzone T; Polis A; Tomassini JE; Lin J; Shah A; Tershakovec AM
    J Clin Lipidol; 2008 Feb; 2(1):25-35. PubMed ID: 21291712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein B/apolipoprotein A-I ratio in relation to the metabolic syndrome, its components, total cholesterol and low-density lipoprotein cholesterol in the population of Georgia.
    Makaridze Z; Giorgadze E; Asatiani K
    Georgian Med News; 2014 Sep; (234):32-9. PubMed ID: 25341235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: the Cardiovascular Risk in Young Finns study.
    Koskinen J; Magnussen CG; Würtz P; Soininen P; Kangas AJ; Viikari JS; Kähönen M; Loo BM; Jula A; Ahotupa M; Lehtimäki T; Ala-Korpela M; Juonala M; Raitakari OT
    Eur J Prev Cardiol; 2012 Dec; 19(6):1296-303. PubMed ID: 21960651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men.
    Wallenfeldt K; Bokemark L; Wikstrand J; Hulthe J; Fagerberg B
    Stroke; 2004 Oct; 35(10):2248-52. PubMed ID: 15345795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of circulating lipoprotein lipase and adiponectin on the particle size of remnant lipoproteins in patients with diabetes mellitus and metabolic syndrome.
    Shirakawa T; Nakajima K; Yatsuzuka S; Shimomura Y; Kobayashi J; Machida T; Sumino H; Murakami M
    Clin Chim Acta; 2015 Feb; 440():123-32. PubMed ID: 25445417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).
    Wang F; Ye P; Hu D; Min Y; Zhao S; Wang Y; Mu Y; Yan X; Li Z; Wei Y; Li J;
    Atherosclerosis; 2014 Nov; 237(1):99-105. PubMed ID: 25238215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Prevalence of Elevated ApoB Levels in Patients with Type 2 Diabetes Not Receiving Lipid-Lowering Therapy.
    Tildesley H; Fraser T; Wise S; Mazanderani A; Aydin C; Johns K; Yu E; Bondy G
    Can J Diabetes; 2009; 33(3):163-9. PubMed ID: 25998591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.
    Watts GF; Ji J; Chan DC; Ooi EM; Johnson AG; Rye KA; Barrett PH
    Clin Sci (Lond); 2006 Sep; 111(3):193-9. PubMed ID: 16700661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
    Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
    Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study.
    Idris I; Tate H; Ahmad A; McCormack T
    J Clin Lipidol; 2011; 5(4):316-23. PubMed ID: 21784378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.